• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Anti-parasite drug targets cancer-causing protein

New York - Researchers have found mebendazole, a widely prescribed drug used to treat parasitic infections, to be a a viable investigational agent for the treatment of chemotherapy-resistant malignant melanoma, ScienceDaily reports.

b>New York - Researchers have found mebendazole, a widely prescribed drug used to treat parasitic infections, to be a a viable investigational agent for the treatment of chemotherapy-resistant malignant melanoma, ScienceDaily reports.

The report, published in the journal Molecular Cancer Research and a phase 1 clinical trial is expected to begin next year. Researchers screened a library of 2,000 well-known drugs and identified benzimidazole agents for their ability to inhibit melanoma growth and induce cell death o malignant melanoma without harming normal melanocytes. The team chose mebendazole for further study because it is well-tolerated, orally available and contains anti-cancer properties, according to ScienceDaily.

Related Videos
3 experts are featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.